Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Hemangiosarcoma × pazopanib × Clear all

Phase

Status

Completed 4 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 7 Sarcoma 6 Carcinoma, Non-Small-Cell Lung 5 Breast Neoplasms 5 Neoplasm Metastasis 4 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Lung Neoplasms 2 Breast Neoplasms, Male 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Unspecified Adult Solid Tumor - Protocol Specific 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Alveolar Soft Part 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Paraganglioma, Extra-Adrenal 1 Paraganglioma 1 Osteosarcoma 1 Neurofibrosarcoma 1 Melanoma 1 Liver Neoplasms 1 Leiomyosarcoma 1 Kidney Neoplasms 1 Hypertension 1 Histiocytoma, Malignant Fibrous 1 Histiocytoma 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1

Interventions

Doxorubicin 2 sintilimab 1 pazopanib 1 Trabectedin 1 TTI-621 1 Paclitaxel 1 Cyproheptadine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02212015 2022-03-22

EVA

Heidelberg University

Phase 2 Terminated

26 enrolled 16 charts

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡